Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy

Chien Feng Li, Hong Lin He, Jaw Yuan Wang, Hsuan Ying Huang, Ting Fe Wu, Chung-Hsi Hsing, Sung Wei Lee, Hao Hsien Lee, Jui Lung Fang, Wen Tsung Huang, Shang Hung Chen

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aims Neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery is an increasingly used therapeutic strategy for advanced rectal cancer, but risk stratification and final outcomes remain suboptimal. Recently, the oncogenic role of the fibroblast growth factor/fibroblast growth factor receptor (FGFR) signalling pathway has been recognised; however, its clinical significance in rectal cancer has not been elucidated. In this study, we identify and validate targetable drivers associated with the FGFR signalling pathway in rectal cancer patients treated with CCRT.

Methods Using a published transcriptome of rectal cancers, we found FGFR2 gene significantly predicted response to CCRT. The expression levels of FGFR2, using immunohistochemistry assays, were further evaluated in 172 rectal cancer specimens that had not received any treatment. Expression levels of FGFR2 were statistically correlated with major clinicopathological features and clinical survival in this valid cohort.

Results High expression of FGFR2 was significantly related to advanced pretreatment tumour (p=0.022) and nodal status (p=0.026), post-treatment tumour (p

Conclusions High expression of FGFR2 is correlated with advanced tumour stage, poor therapeutic response and worse survival in rectal cancer patients receiving neoadjuvant CCRT. These findings indicate that FGFR2 is a prognostic factor for treating rectal cancer.

Original languageEnglish
Pages (from-to)1056-1061
Number of pages6
JournalJournal of Clinical Pathology
Volume67
Issue number12
DOIs
Publication statusPublished - Dec 1 2014
Externally publishedYes

Fingerprint

Receptor, Fibroblast Growth Factor, Type 2
Chemoradiotherapy
Rectal Neoplasms
Fibroblast Growth Factor Receptors
Neoplasms
Survival
Fibroblast Growth Factors
Therapeutics
Transcriptome
Immunohistochemistry

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Cite this

Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy. / Li, Chien Feng; He, Hong Lin; Wang, Jaw Yuan; Huang, Hsuan Ying; Wu, Ting Fe; Hsing, Chung-Hsi; Lee, Sung Wei; Lee, Hao Hsien; Fang, Jui Lung; Huang, Wen Tsung; Chen, Shang Hung.

In: Journal of Clinical Pathology, Vol. 67, No. 12, 01.12.2014, p. 1056-1061.

Research output: Contribution to journalArticle

Li, CF, He, HL, Wang, JY, Huang, HY, Wu, TF, Hsing, C-H, Lee, SW, Lee, HH, Fang, JL, Huang, WT & Chen, SH 2014, 'Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy', Journal of Clinical Pathology, vol. 67, no. 12, pp. 1056-1061. https://doi.org/10.1136/jclinpath-2014-202551
Li, Chien Feng ; He, Hong Lin ; Wang, Jaw Yuan ; Huang, Hsuan Ying ; Wu, Ting Fe ; Hsing, Chung-Hsi ; Lee, Sung Wei ; Lee, Hao Hsien ; Fang, Jui Lung ; Huang, Wen Tsung ; Chen, Shang Hung. / Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy. In: Journal of Clinical Pathology. 2014 ; Vol. 67, No. 12. pp. 1056-1061.
@article{8eb92bdd47a74d8fbcbe3f3c9975c607,
title = "Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy",
abstract = "Aims Neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery is an increasingly used therapeutic strategy for advanced rectal cancer, but risk stratification and final outcomes remain suboptimal. Recently, the oncogenic role of the fibroblast growth factor/fibroblast growth factor receptor (FGFR) signalling pathway has been recognised; however, its clinical significance in rectal cancer has not been elucidated. In this study, we identify and validate targetable drivers associated with the FGFR signalling pathway in rectal cancer patients treated with CCRT.Methods Using a published transcriptome of rectal cancers, we found FGFR2 gene significantly predicted response to CCRT. The expression levels of FGFR2, using immunohistochemistry assays, were further evaluated in 172 rectal cancer specimens that had not received any treatment. Expression levels of FGFR2 were statistically correlated with major clinicopathological features and clinical survival in this valid cohort.Results High expression of FGFR2 was significantly related to advanced pretreatment tumour (p=0.022) and nodal status (p=0.026), post-treatment tumour (pConclusions High expression of FGFR2 is correlated with advanced tumour stage, poor therapeutic response and worse survival in rectal cancer patients receiving neoadjuvant CCRT. These findings indicate that FGFR2 is a prognostic factor for treating rectal cancer.",
author = "Li, {Chien Feng} and He, {Hong Lin} and Wang, {Jaw Yuan} and Huang, {Hsuan Ying} and Wu, {Ting Fe} and Chung-Hsi Hsing and Lee, {Sung Wei} and Lee, {Hao Hsien} and Fang, {Jui Lung} and Huang, {Wen Tsung} and Chen, {Shang Hung}",
year = "2014",
month = "12",
day = "1",
doi = "10.1136/jclinpath-2014-202551",
language = "English",
volume = "67",
pages = "1056--1061",
journal = "Journal of Clinical Pathology - Clinical Molecular Pathology",
issn = "0021-9746",
publisher = "BMJ Publishing Group",
number = "12",

}

TY - JOUR

T1 - Fibroblast growth factor receptor 2 overexpression is predictive of poor prognosis in rectal cancer patients receiving neoadjuvant chemoradiotherapy

AU - Li, Chien Feng

AU - He, Hong Lin

AU - Wang, Jaw Yuan

AU - Huang, Hsuan Ying

AU - Wu, Ting Fe

AU - Hsing, Chung-Hsi

AU - Lee, Sung Wei

AU - Lee, Hao Hsien

AU - Fang, Jui Lung

AU - Huang, Wen Tsung

AU - Chen, Shang Hung

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Aims Neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery is an increasingly used therapeutic strategy for advanced rectal cancer, but risk stratification and final outcomes remain suboptimal. Recently, the oncogenic role of the fibroblast growth factor/fibroblast growth factor receptor (FGFR) signalling pathway has been recognised; however, its clinical significance in rectal cancer has not been elucidated. In this study, we identify and validate targetable drivers associated with the FGFR signalling pathway in rectal cancer patients treated with CCRT.Methods Using a published transcriptome of rectal cancers, we found FGFR2 gene significantly predicted response to CCRT. The expression levels of FGFR2, using immunohistochemistry assays, were further evaluated in 172 rectal cancer specimens that had not received any treatment. Expression levels of FGFR2 were statistically correlated with major clinicopathological features and clinical survival in this valid cohort.Results High expression of FGFR2 was significantly related to advanced pretreatment tumour (p=0.022) and nodal status (p=0.026), post-treatment tumour (pConclusions High expression of FGFR2 is correlated with advanced tumour stage, poor therapeutic response and worse survival in rectal cancer patients receiving neoadjuvant CCRT. These findings indicate that FGFR2 is a prognostic factor for treating rectal cancer.

AB - Aims Neoadjuvant concurrent chemoradiotherapy (CCRT) followed by surgery is an increasingly used therapeutic strategy for advanced rectal cancer, but risk stratification and final outcomes remain suboptimal. Recently, the oncogenic role of the fibroblast growth factor/fibroblast growth factor receptor (FGFR) signalling pathway has been recognised; however, its clinical significance in rectal cancer has not been elucidated. In this study, we identify and validate targetable drivers associated with the FGFR signalling pathway in rectal cancer patients treated with CCRT.Methods Using a published transcriptome of rectal cancers, we found FGFR2 gene significantly predicted response to CCRT. The expression levels of FGFR2, using immunohistochemistry assays, were further evaluated in 172 rectal cancer specimens that had not received any treatment. Expression levels of FGFR2 were statistically correlated with major clinicopathological features and clinical survival in this valid cohort.Results High expression of FGFR2 was significantly related to advanced pretreatment tumour (p=0.022) and nodal status (p=0.026), post-treatment tumour (pConclusions High expression of FGFR2 is correlated with advanced tumour stage, poor therapeutic response and worse survival in rectal cancer patients receiving neoadjuvant CCRT. These findings indicate that FGFR2 is a prognostic factor for treating rectal cancer.

UR - http://www.scopus.com/inward/record.url?scp=84910148683&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84910148683&partnerID=8YFLogxK

U2 - 10.1136/jclinpath-2014-202551

DO - 10.1136/jclinpath-2014-202551

M3 - Article

VL - 67

SP - 1056

EP - 1061

JO - Journal of Clinical Pathology - Clinical Molecular Pathology

JF - Journal of Clinical Pathology - Clinical Molecular Pathology

SN - 0021-9746

IS - 12

ER -